New hepatitis b drug tested in kidney patients
NCT ID NCT07342881
First seen Jan 28, 2026 · Last updated May 23, 2026 · Updated 18 times
Summary
This early-stage study looks at how the body processes a single dose of pevifoscorvir sodium (ALG-000184) in people with chronic hepatitis B who have different levels of kidney function. About 30 adults with severe, mild, moderate, or no kidney impairment will take part. The goal is to measure drug levels in the blood and urine, and to check for any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Genesis Clinical Trials
RECRUITINGTampa, Florida, 33603, United States
Contact Email: •••••@•••••
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.